English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

MPS-Authors
/persons/resource/persons16093

Zweckstetter,  M.
Research Group of Protein Structure Determination using NMR, MPI for biophysical chemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (public)

3357677.pdf
(Publisher version), 2MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Oliveira, L. M. A., Gasser, T., Edwards, R., Zweckstetter, M., Melki, R., Stefanis, L., et al. (2021). Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. NPJ Parkinsons Disease, 7: 65. doi:10.1038/s41531-021-00203-9.


Cite as: http://hdl.handle.net/21.11116/0000-000A-31DE-5
Abstract
With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.